Wound healing is a complex process that is essential to provide skin homeostasis. Infection with pathogenic bacteria such as Staphylococcus aureus can lead to chronic wounds, which are challenging to heal. Previously, we demonstrated that the antimicrobial endotoxin-neutralizing peptide Pep19-2.5 promotes artificial wound closure in keratinocytes. Here, we investigated the mechanism of peptide-induced cell migration and if Pep19-2.5 accelerates wound closure in vivo.
Introduction
The skin provides a protective barrier against invading pathogens, which is maintained by a complex network of physical, chemical and immunological components (Bangert et al., 2011) . Disruption of the skin barrier leads to wound formation, initiating a well-orchestrated wound healing process to efficiently close the wound (Kondo and Ishida, 2010) . Three stages of wound healing are described comprising the inflammatory phase with blood clot formation and immune cell invasion, the re-epithelialization phase where keratinocytes of the epidermis and fibroblasts of the dermis migrate and proliferate to close the wound and the remodelling phase with collagen synthesis and formation of a mature scar (Werner and Grose, 2003) . Inadequate wound recovery can lead to the formation of chronic wounds, which are challenging to heal and frequently remain in the inflammatory stage (Frykberg and Banks, 2015) .
Bacterial colonization of wounds represents a pivotal complication impairing or delaying wound healing (Demidova-Rice et al., 2012) . Staphylococcus aureus is the most common cause of nosocomial wound infections and skin and soft tissue infections (SSTIs), especially methicillin-resistant S. aureus (MRSA) which accounts for 50% of all SSTIs. In contrast, chronic and postoperative wounds are predominantly infected with Gram-negative bacteria such as Pseudomonas aeruginosa, Enterococcus and Acinetobacter species (Cardona and Wilson, 2015; Esposito et al., 2016; Guillamet and Kollef, 2016) . These organisms belong to the so-called ESKAPE pathogens, which represent the most recalcitrant bacteria and are resistant to almost all common antibiotics (Santajit and Indrawattana, 2016) . Increasing resistance is also reported against topical antibiotics such as mupirocin and fusidic acid (Mendoza and Tyring, 2010; Guillamet and Kollef, 2016) . Thus, new treatment options are urgently needed.
Endogenous antimicrobial peptides (AMPs) are upregulated in all stages of wound healing demonstrating their essential role for wound recovery. As they not only display direct antimicrobial effects but additionally show various hostdirected effects in each phase of the wound healing process, they offer promise as candidates for the treatment of acute and chronic wounds (Mangoni et al., 2016; Pfalzgraff et al., 2018) . In particular, promotion of cell migration in vitro and re-epithelialization in vivo were demonstrated to be essentially regulated by AMPs (Carretero et al., 2008) . Several AMPs were shown to stimulate keratinocyte migration via EGF receptor (EGFR) signalling, such as the frog skinderived AMP esculentin-1a(1-21)NH 2 (Di Grazia et al., 2015) or temporins A and B (Di Grazia et al., 2014) .
We previously showed that the antimicrobial endotoxinneutralizing peptide Pep19-2.5 promotes artificial wound closure in keratinocytes via P2X receptors and subsequent metalloprotease-dependent transactivation of the EGFR . Additionally, we demonstrated a strong anti-inflammatory effect in skin cells against cell wall-derived inflammatory toxins of Gram-positive and Gram-negative bacteria Pfalzgraff et al., 2017) .
To gain further insights into the mechanism of Pep19-2.5-induced cell migration, we examined the potential involvement and role of purinergic receptors and characterized signalling pathways leading to metalloprotease-mediated EGFR transactivation. Furthermore, we investigated if Pep19-2.5 is capable of accelerating wound closure in vivo.
Methods

Cell culture
The immortalized keratinocyte cell line HaCaT (passage 40-55) (CLS Cell Lines Service, Eppelheim, Germany) and HEK293 cells (passage 5-10) (ACC 305, DSMZ, Braunschweig, Germany) were cultured in RPMI-1640 (Sigma-Aldrich, Taufkirchen, Germany) with 11.1 mM glucose containing 2 mM L-glutamine and 10% (v . 
Peptides
Pep19-2.5 (GCKKYRRFRWKFKGKFWFWG), also termed Aspidasept, LL-37 amide trifluoroacetate salt and melittin (GIGAVLKVLTTGLPALISWIKRKRQQ) were purchased from Bachem (Bubendorf, Switzerland). All peptides were of a purity level of at least 95% as determined by HPLC and MS.
Cell transfection
HEK293 cells were seeded in 24-well plates and transfected after 24 h with 1 μg plasmid DNA encoding for the human P2X7 receptor (pUNO1-hP2RX7a, Invivogen) using lipofectamine (Thermo Scientific, Darmstadt, Germany) according to the manufacturer's instructions. Cells were grown for 24 h prior to stimulation. Transfection efficiency was monitored with quantitative RT-PCR (qPCR).
RNA isolation, cDNA synthesis and quantitative RT-PCR
Total RNA isolation, cDNA synthesis and qPCR were performed as described previously (Weindl et al., 2007; Weindl et al., 2011) . The following primers (synthesized by TIB Molbiol, Germany) were used: G6PD, 5 0 -ATCGACCACTA CCTGGGCAA-3 0 and 5 0 -TTCTGCATCACGTCCCGGA-3 0 ; hP2X7R-1, 5 0 -TGTG-CCTACAGGTGCTACGCC-3 0 and 5 0 -GCCCTTCACTCTTCGGAAACTC-3 0 ; SDHA, 5 0 -TGGGAACAA GAGGGCATCTG-3 0 and 5 0 -CCACCACTGCATCAAATTC ATG-3 0 ; YWHAZ, 5 0 -AGACGGAAGGTGCTGAGAAA-3 0 and 5 0 -GAAGCATTGGGGATCAAGAA-3 0 . Fold difference in gene expression was normalized to the housekeeping gene YWHAZ, because detailed preliminary investigations using three different housekeeping genes (G6PD, SDHA, and YWHAZ) indicated that this gene showed the most constant level of expression.
Cell viability
Cell viability in the presence of the inhibitors was determined by the MTT assay as described previously (Do et al., 2014) .
In vitro scratch assay
The scratch assay was performed with HaCaT cells and HEK293 cells as described previously . Cells were preincubated for 2 h with 5 μg·mL À1 mitomycin C (Tocris, Wiesbaden-Nordenstadt, Germany) to prevent cell proliferation. Pep19-2.5 was added in the absence or presence of the non-competitive P2X7 receptor antagonist KN-62 (10 μM; Sigma-Aldrich), the irreversible P2X7R receptor antagonist oxidized ATP (oxATP; 100 μM; Sigma-Aldrich), the ATPase hexokinase (1 U·mL
À1
; Sigma-Aldrich), the mitochondrially targeted antioxidant MitoTEMPO (10 μM) or the intracellular calcium chelator BAPTA-AM (10 μM) (both from Biomol, Hamburg, Germany). TGFβ1 (1 ng·mL À1 , Miltenyi Biotech, Bergisch Gladbach, Germany) or growth medium served as positive control. Scratches were documented under a microscope with 10× (HaCaT cells) or 5× (P2X7 receptor-transfected HEK293 cells) magnification (Axiovert 135; Carl Zeiss, Jena, Germany) equipped with a digital SLR camera (Canon EOS 1000D; Canon Germany, Krefeld, Germany) immediately after the scratching procedure and once more when kept at 37°C and 5% CO 2 for 20-24 h. Pictures were taken exactly at the same position before and after the incubation to document artificial wound closure. The experiments were repeated two or four times, and representative pictures are shown.
Western blotting
After preincubation for 1 h with KN-62 (10 μM), MitoTEMPO (10 μM) or BAPTA-AM (10 μM) HaCaT cells were stimulated for 15 min for detection of phospho-ERK1/2. Subsequently, cells were lysed and prepared as described previously (Bock et al., 2016) . After gel electrophoresis and blotting, membranes were blocked with 5% BSA (Sigma-Aldrich) for 1 h at 37°C, membranes were incubated with anti- 
ATP assay
The ATP assay was performed with CellTiter-Glo 2.0 (Promega, Mannheim, Germany) according to the manufacturer's instructions; 40,000 HaCaT cells per well were seeded in a 96-well plate overnight. Cells were stimulated with increasing concentrations of Pep19-2.5 or melittin, and supernatant was collected after 30 min and transferred to a white 96-well plate (Greiner Bio-One, Frickenhausen, Germany).
A total of 100 μL of CellTiter-Glo 2.0 per well was added and incubated for 10 min. Afterwards, luminescence was measured with a plate reader (FLUOstar Optima).
Calcium assay
A calcium assay was performed with the Ca 2+ -sensitive dye Calbryte 520 (Biomol, Hamburg, Germany) following the manufacturer's instructions; 40,000 HaCaT cells per well in a 96-well plate were seeded overnight. A total of 100 μL of 10 μM Calbryte 520 and 2 mM probenecid (Tocris, Wiesbaden, Germany) in HHBS (final concentration 5 μM and 1 mM respectively) were added to the wells, and the cells were incubated at 37°C for 45 min. The dye loading medium was replaced with 200 μM HHBS containing 1 mM probenecid. A total of 50 μL of samples were added with a pump, and fluorescence intensity was recorded over time immediately after adding the samples in a plate reader (FLUOstar Optima, BMG Labtech, Offenburg, Germany; excitation/emission = 492/520 nm).
Mitochondrial ROS
Mitochondrial ROS release was measured with MitoSOX Red (Thermo Scientific) according to the manufacturer's instructions; 100,000 HaCaT cells per well in a 24-well plate were seeded overnight. After 30 min stimulation with Pep19-2.5 or antimycin A (Sigma), cells were washed with HBSS and loaded with 5 μM MitoSOX Red for 30 min at 37°C and 5% CO 2 . Afterwards, cells were analysed by flow cytometry (CytoFLEX, Beckman Coulter, Krefeld, Germany).
Mouse wound healing model
All animal experiments were approved by the Animal Research Committee of University of Navarra (Protocol 013-17) and by 'Departamento de Salud del Gobierno de Navarra' (Approval code 2017/122402) and were carried out in specific pathogen-free female BALB/C mice, 6-7 weeks of age and weighing 20-22 g (Harlan Interfauna Iberica SA, Barcelona, Spain). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Mice were housed in aseptic rooms in the Animal Facility of the University of Navarra with 12 h light/dark cycles and under a constant temperature of 22°C. Access to water and food was ad libitum. Each cage contained five mice with sawdust as bedding that was changed daily. Mice were randomly distributed into experimental groups (n = 5 animals per group). Animal cages were housed in a random order on the shelves, and all measurements were done in a random order with the investigator being blinded to the treatment received by each experimental unit. After 1 week of acclimatization, mice were anaesthetized with an i.p. injection of ketamine (100 mg·kg À1 ; Merial S.A. Barcelona, Spain) and xylazine (5 mg·kg À1 ; Bayer Hispania, S.L. Barcelona, Spain) and dorsally wounded with a 5 mm biopsy punch (Stiefel Farma, Madrid, Spain). Afterwards, wounds were topically treated with 20 μL of vehicle (pyrogen-free saline), Pep19-2.5 (400 μg·mL À1 ) or LL-37 (400 μg·mL À1 ) twice per day for 6 days. Every second day pictures of the wounds were taken. On day 6 post-wounding, mice were killed by cervical dislocation. Although we used the Shrum scale of severity (Shrum et al., 2014) , its application was not required, since animals suffered no apparent discomfort at any time. For the mouse model of infected wounds, mice were dorsally wounded and immediately infected with 3.5Á10 4 CFU MRSA (ATCC 43300) in 10 μL pyrogen-free saline per wound. Afterwards, wounds were topically treated as described above. A schematic diagram of the study design is presented in Figure S1 . Care and handling of the animals were in accordance with the ICH and OECD international guidelines.
Statistical analysis
Data are depicted as means ± SD. All experiments were performed at least five times independently. Statistical significance of differences was determined by two-way ANOVA (for animal experiments) or one-way ANOVA (Western blots) followed by Bonferroni's multiple comparison test and considered significant at P < 0.05. A post test was only carried out if P < 0.05 was achieved in ANOVA and homogeneity of variances was given. Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad software, San Diego, USA).
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) .
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c) .
Results
P2X7 receptor is critically involved in Pep19-2.5-induced cell migration in vitro
We could previously show that purinergic receptors appear to be involved in Pep19-2.5-induced keratinocyte migration . Various AMPs can modulate or activate the P2X7 receptor (Elssner et al., 2004; Ferrari et al., 2004; Sommer et al., 2012) which plays a critical role in epithelial cell migration (Minns et al., 2016) . To gain further insights into the role of purinergic receptors for Pep19-2.5-promoted cell migration, we therefore performed a wound scratch assay with P2X7 receptor antagonists in HaCaT keratinocytes. Comparable to primary human keratinocytes , we observed a concentration-dependent increase in Pep19-2.5-induced cell migration ( Figure 1A ). While the most effective peptide concentration 1 μg·mL À1 accelerated cell migration comparable to the positive control TGF-β, both the non-competitive P2X7 receptor antagonist KN-62 and the irreversible antagonist oxATP abrogated peptide-induced cell migration ( Figure 1B ). Additionally, Pep19-2.5-induced phosphorylation of ERK1/2 was reduced in the presence of KN-62 ( Figure 1C, D) . Cell viability was at least 80% for the applied concentrations of the inhibitors as determined by the MTT assay ( Figure S2 ). The pivotal role of the P2X7 receptor in Pep19-2.5-promoted cell migration was further confirmed in P2X7 receptor-transfected HEK293 cells. In HEK293-null cells lacking the P2X7 receptor, growth medium, which served as positive control, accelerated artificial wound closure, while Pep19-2.5 was not able to accelerate cell migration compared to the untreated control in the absence of the P2X7 receptor ( Figure 1E ). However, in P2X7 receptor-transfected HEK293 cells ( Figure S3 ), Pep19-2.5 strongly induced cell migration which was suppressed in the presence of KN-62 ( Figure 1F ).
Pep19-2.5-induced cell migration requires ATP
Recent studies reveal an involvement of the P2X7 receptor ligand ATP in peptide-induced P2X7 receptor activation, as demonstrated for the bee venom AMP melittin which concentration-dependently evoked ATP release from HaCaT keratinocytes (Sommer et al., 2012) . Therefore, we investigated if the ATPase hexokinase is able to block Pep19-2.5-induced cell migration. In fact, hexokinase reduced Pep19-2.5-induced HaCaT cell migration (Figure 2A) . However, in contrast to the positive control melittin which concentration-dependently increased ATP, Pep19-2.5 did not induce ATP release ( Figure 2B ).
Pep19-2.5-enhanced keratinocyte cell migration depends on intracellular calcium and mitochondrial ROS As P2X7 receptor activation leads to calcium mobilization, we further investigated if Pep19-2.5 triggers calcium release. Pep19-2.5 increased cytosolic calcium even stronger than the positive control ATP when using a buffer containing calcium ( Figure 3A) , while the peptide-induced, but not the ATP-induced, increase was lower in the absence of extracellular calcium ( Figure 3B ). Since calcium can induce mitochondrial ROS generation (Gorlach et al., 2015) , we examined if Pep19-2.5 can increase mitochondrial ROS in HaCaT cells. Indeed, we observed an increase of mitochondrial ROS for Pep19-2.5 which was less pronounced compared to the ROS generator antimycin A ( Figure 3C ). To determine if intracellular calcium and ROS are involved in peptide-mediated EGFR transactivation, we investigated phosphorylation of ERK1/2 and observed a reduction of phosphorylated ERK1/2 when preincubating with the intracellular calcium chelator BAPTA-AM and the mitochondrially targeted antioxidant MitoTEMPO compared to the peptide alone ( Figure 3D ). Additionally, both inhibitors were able to block peptide-induced HaCaT cell migration ( Figure 3E ). The inhibitors did not decrease cell viability in the MTT assay ( Figure S2 ).
Pep19-2.5 enhances wound closure in vivo
Since Pep19-2.5 strongly promotes keratinocyte migration in vitro, we hypothesized that the peptide accelerates reepithelialization in vivo and therefore examined its in vivo wound healing properties in a mouse model of excisional wound healing. LL-37 was used as reference peptide (Carretero et al., 2008) . Topical treatment with Pep19-2.5 considerably enhanced the rate of wound closure compared with the vehicle-treated group ( Figure 4A, B) . The wound diameter of Pep19-2.5-and LL-37-treated wounds decreased after treatment, while the vehicle-treated wounds initially increased in diameter and showed clear signs of inflammation. Already at day 2 after wounding, we observed a significant difference in wound diameter between the peptide-and vehicle-treated wounds. At day 6, wound diameters of Pep19-2.5-treated mice were reduced by 50-80%, while LL-37-treated mice showed a wound diameter reduction between 25 and 50% ( Figure 4B ) and the wound diameter of 2 out of 5 vehicle-treated mice was not reduced or even increased (data not shown).
Pep19-2.5 promotes closure of MRSA-infected wounds in vivo
Additionally, to inducing cell migration in vitro, Pep19-2.5 reduces inflammation in different skin cells stimulated with LPS and lipoproteins and neutralizes the pro-inflammatory activity of the S. aureus lipoprotein SitC (Martinez de Tejada Pfalzgraff et al., 2016) . Since S. aureus is the major cause for wound infections (Esposito et al., 2016) , we sought to determine the wound healing activities of Pep19-2.5 in a mouse model of MRSA skin wound infection. On day 2 post-infection, all wounds showed clear signs of inflammation such as redness and swelling ( Figure 5A ). The wound diameter of infected, vehicle-treated wounds increased up to day 2 and afterwards, only slowly decreased to its initial size at day 0 ( Figure 5B ). In contrast, Pep19-2.5-and LL-37-treated as well as non-infected, vehicle-treated wounds decreased in diameter as soon as day 2 posttreatment compared to infected, vehicle-treated control. After 6 days, wound diameters of peptide-treated mice were reduced by 25-60%.
Discussion
Impaired wound healing represents a considerable health burden affecting morbidity, mortality and health costs (Serra et al., 2015) . In this study, we demonstrated that the antimicrobial endotoxin-neutralizing peptide Pep19-2.5 additionally to its previously reported anti-inflammatory and cell migration-promoting activity in vitro accelerates wound closure in vivo of non-infected as well as MRSA-infected wounds in mice. Furthermore, we provide significant insights into the mechanism involved in peptide-induced cell migration suggesting a crucial role for the P2X7 receptor, intracellular calcium and ROS ( Figure 6 ). Endogenous AMPs play an essential role during wound recovery (Mangoni et al., 2016; Pfalzgraff et al., 2018) . Early studies revealed that antibodies against the natural AMP LL-37 were able to inhibit re-epithelialization, while LL-37 gene transfer to excisional wounds increased reepithelialization and granulation tissue formation in mice (Heilborn et al., 2003; Carretero et al., 2008) . EGFR transactivation has been implicated in this mechanism, which we could recently also confirm for Pep19-2.5 . Transactivation of EGFR occurs via metalloprotease-mediated shedding of EGFR ligands that subsequently activate EGFR and downstream signalling. Furthermore, we and other groups reported that purinergic receptors play a pivotal bridging role in the peptide- HaCaT cells were stimulated with increasing concentrations of melittin or Pep19-2.5 for 30 min, supernatants were collected and ATP release was quantified with an ATP assay. Mean + SD (control, n = 7; Pep19-2.5, n = 5; melittin, n = 6).
metalloprotease/EGFR stimulatory axis (Sommer et al., 2012; Sperrhacke et al., 2014) . Here, we show a crucial role for the P2X7 receptor for peptide-induced phosphorylation of ERK1/2. This is in accordance with previous data for the keratinocyte-derived cationic peptide SPINK9 and melittin, the major component of bee venom, showing a decrease in peptide-induced ERK1/2 phosphorylation with P2
receptor antagonists and an increase in peptide-mediated ERK1/2 phosphorylation in P2X7 receptor-transfected HEK293 cells (Sommer et al., 2012; Sperrhacke et al., 2014) . However, these studies did not show a direct involvement of the P2X7 receptor in peptide-induced cell migration. In contrast, we provide evidence that the P2X7 receptor is mandatory for peptide-induced keratinocyte Anti-endotoxin peptides promote wound healing migration which is in line with recent findings for LL-37 (Comune et al., 2017) . The importance of P2X7 receptormediated cell migration during wound healing in vivo remains to be established. To get more insights into the mechanism of Pep19-2.5-mediated P2X7 receptor activation, we investigated the role of the P2X7 receptor ligand ATP. For melittin, phosphorylation of ERK1/2 in P2X7 receptor-transfected HEK cells was reduced in the presence of the ATPase apyrase indicating a critical role for ATP in melittin-induced P2X7 receptor activation. However, in HaCaT keratinocytes, the ATPase hexokinase did not completely abrogate melittin-induced ERK1/2 phosphorylation suggesting the involvement of more complex mechanisms (Sommer et al., 2012) . For SPINK9, ATP release was not increased and ATPases did not reduce EGFR transsignalling (Sperrhacke et al., 2014) . Therefore, a general role for ATP in peptide-induced P2X7 receptor activation still awaits further clarification. We could demonstrate that Pep19-2.5-induced keratinocyte migration was reduced in the presence of the ATPase hexokinase, yet Pep19-2.5 failed to increase ATP levels. We also confirmed that non-toxic concentrations of melittin increase ATP release in the nM range in HaCaT cells (Sommer et al., 2012) . Given the low affinity of ATP for the P2X7 receptor, concentrations in the mM range are required in vitro which are not commonly found in the extracellular milieu (Arulkumaran et al., 2011) . Therefore, we suggest that Pep19-2.5 and possibly melittin rather increase the sensitivity of the P2X7 receptor to ATP than directly Figure 4 Pep19-2.5 accelerates wound healing in vivo. BALB/c mice were dorsally wounded and afterwards topically treated with vehicle (pyrogen-free saline), Pep19-2.5 (400 μg·mL À1 ) or LL-37 (400 μg·mL À1 ) twice per day for 6 days. (A) Pictures are representative for five mice per group. (B) Wound diameter for vehicle-, Pep19-2.5-and LL-37-treated wounds is depicted for day 0 to day 6. Data are mean ± SD (n = 5). Two-way ANOVA followed by Bonferroni's post hoc test. *P < 0.05, #P < 0.05. Pep19-2.5 (*) or LL-37 (#) versus vehicle-treated control.
activating the receptor. However, it is unclear if Pep19-2.5 acts as an allosteric modulator of P2X7 receptor similar to polymyxin B (Ferrari et al., 2004) . To analyse the mechanism following peptide-induced P2X7 receptor activation, we examined the capability of Pep19-2.5 to increase cytosolic calcium as P2X7 receptor activation results in increased intracellular calcium. Indeed, Pep19-2.5 induced a strong calcium release. Notably, in the absence of extracellular calcium, the calcium release induced by the peptide was decreased, but not completely abolished, compared to the release in the presence of extracellular calcium. This indicates that the observed calcium increase might be due to calcium influx from the extracellular milieu as well as release from intracellular stores as demonstrated for melittin (Tomasinsig et al., 2008) . Recent studies indicate that calcium influx triggered by ATP-induced P2X7 receptor activation leads to ADAM10-mediated ectodomain shedding of CD44 resulting in formation of soluble CD44 (sCD44) (Stamenkovic and Yu, 2009) . Thus, the peptide-increased calcium influx could further induce sCD44-mediated allosteric activation of the P2X7 receptor through a positive feed-back loop (Moura et al., 2015) .
Figure 5
Pep19-2.5 promotes wound closure in MRSA-infected wounds. BALB/c mice were dorsally wounded and subsequently infected with 3.5Á10 4 CFU MRSA in 10 μL pyrogen-free saline per wound. Afterwards, wounds were topically treated with vehicle (pyrogen-free saline) for infected or noninfected wounds, Pep19-2.5 (400 μg·mL À1 ) or LL-37 (400 μg·mL À1 ) twice per day for 6 days. (A) Pictures are representative for five mice per group. (B) Wound diameter for vehicle-, Pep19-2.5-and LL-37-treated wounds is depicted for day 0 to day 6. Data are mean ± SD (n = 5). Two-way ANOVA followed by Bonferroni's post hoc test. *P < 0.05, #P < 0.05. Vehicle-treated, non-infected control (*), Pep19-2.5 (*) or LL-37 (#) versus vehicle-treated, MRSA-infected control.
As intracellular calcium is able to induce ROS formation in keratinocytes (Masaki et al., 2009) , we investigated the ability of Pep19-2.5 to trigger mitochondrial ROS release. Pep19-2.5-induced mitochondrial ROS release from HaCaT cells and ROS is able to activate ADAMs (Scott et al., 2011) . Therefore, we hypothesize that the role of the P2X7 receptor in the peptide-metalloprotease/EGFR stimulatory axis is implemented via intracellular calcium-induced ROS release followed by ADAM activation which in turn mediates EGFR transactivation. This is further supported by our observation that peptide-induced ERK1/2 phosphorylation and keratinocyte migration depends on calcium and ROS. Importantly, low concentrations of ROS can induce keratinocyte migration, while high concentrations can lead to chronic inflammation (Andre-Levigne et al., 2017) . Therefore, low amounts of ROS induced by Pep19-2.5 might be sufficient to promote cell migration without inducing cytotoxicity.
Additionally, to promotion of cell migration in vitro, AMPs support wound healing in vivo by sustaining wound reepithelialization. The small peptide tiger 17, which promoted keratinocyte migration as well as proliferation in vitro, was capable of improving re-epithelialization in vivo . AH90, a peptide from frog skin, accelerated wound closure in vivo in non-infected wounds and improved epidermal and dermal regeneration and granulation tissue formation . Pep19-2.5 treatment resulted in rapid wound closure compared to vehicle-treated wounds as soon as day 2 post-treatment comparable to the innate defence regulator peptide IDR-1018 which also improved wound closure already at day 2 after wounding (Steinstraesser et al., 2012) . It remains to be determined whether Pep19.2-5 modulates other wound healing-promoting activities such as induction of angiogenesis, as recently reported for IDR-1018 (MarinLuevano et al., 2018) . Considering the distinct mode of action of the aforementioned AMPs compared to Pep19-2.5, involving the release of TGF-β or immunomodulatory activities, a combination of these peptides with Pep19-2.5 might be of clinical benefit due to a possible synergistic effect.
A potential limitation of our study is that the in vitro findings may be less relevant in vivo. Wound healing in mice, but not in humans, mainly occurs via contraction and not reepithelialization and granulation tissue formation (Wong et al., 2011) . This might explain, at least partially, the less pronounced effect of Pep19-2.5 in the mouse wound healing studies compared to the potent effect on keratinocyte migration. Thus, alternative preclinical models should be considered in future research (Ansell et al., 2012) .
S. aureus-secreted toxins, virulence factors and exoproteins can delay wound healing and may lead to prolonged inflammation and chronic infection. Additionally, skin infections caused by S. aureus or P. aeruginosa frequently lead to invasive infections that might result in sepsis (Thangamani et al., 2015; Guillamet and Kollef, 2016) . Notably, the inflammatory response after bacterial infection contributes to the clinical severity of S. aureus skin infection rather than the bacterial burden (Mohamed et al., 2014) . We could previously demonstrate a strong anti-inflammatory effect of Pep19-2.5 against pathogenicity factors of Gram-positive and Gramnegative bacteria in skin cells . Here, we show that Pep19-2.5 is able to accelerate wound closure in MRSA-infected wounds additionally to non-infected wounds suggesting an additional mechanism besides promoting re-epithelialization. Importantly, Pep19-2.5 shows strong activity against diverse Toll-like receptor (TLR)2 agonists found in S. aureus including lipopeptides such as SitC, peptidoglycans and lipoteichoic acid (Martinez de Tejada et al., 2015) . The relatively high MIC value of 128 μg·mL À1 for MRSA (Gutsmann et al., 2010) suggests that Pep19-2.5, apart from the cell migration-promoting activity, improves wound healing of infected wounds due to an antiinflammatory effect rather than a direct antimicrobial effect. This mode of action has been demonstrated for other AMPs (Thangamani et al., 2015; Mohamed et al., 2016) and also Pep19-2.5 which directly binds to heat-killed MRSA and reduces heat-killed MRSA-induced inflammation in ex vivo lung tissues (Heinbockel et al., 2013) . Pep19-2.5 was designed to neutralize cell-wall derived bacterial toxins, thus acting as an anti-inflammatory agent and inhibiting TLR2 and TLR4-mediated responses. In contrast, treatment with conventional antibiotics may trigger the secretion of pro-inflammatory cytokines by releasing pathogenicity factors and therefore even worsen the outcome of an infection, as demonstrated for ciprofloxacin (Heinbockel et al., 2013) . By displaying activity against Figure 6 Proposed molecular mechanism of Pep19-2.5-induced keratinocyte migration via the P2X7 receptor and EGFR. Pep19-2.5 induces P2X7 receptor activation indirectly or by acting as an allosteric modulator, thus increasing its sensitivity to the extracellular ligand ATP. P2X7 receptor activation leads to Ca 2+ mobilization, followed by mitochondrial ROS release. ROS, in turn, trigger metalloprotease-mediated EGFR transactivation resulting in downstream signalling via ERK1/2 and finally leading to keratinocyte migration.
pathogenicity factors of both Gram-positive and Gramnegative bacteria, Pep19-2.5 might also be used for the treatment of polymicrobial wound infections in a combination with an antibiotic to merge the anti-inflammatory and re-epithelialization promoting effect of the peptide with the direct antimicrobial effect of the antibiotic. Thus, future studies should investigate application of Pep19-2.5 in combination with antibiotics for the treatment of infected wounds. Additionally, alternative delivery methods and formulations should be considered since conjugation of LL-37 to gold nanoparticles improved in vitro and in vivo wound healing activity compared to soluble LL-37 (Comune et al., 2017) .
In conclusion, we provide evidence for the potential application of Pep19-2.5 in the treatment of non-infected and S. aureus-infected wounds and give insights into the mechanism involved in Pep19-2.5-induced wound healing. Thangamani S, Nepal M, Chmielewski J, Seleem MN (2015) . Antibacterial activity and therapeutic efficacy of Fl-P (R) P (R) P (L)-5, a cationic amphiphilic polyproline helix, in a mouse model of staphylococcal skin infection. Drug Des Devel Ther 9: 5749-5754. 
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